The technology will enable CCS to provide its customers with transfected non-tumor origin cell lines including CAP-TTM cells, designed for use in cell based assays and protein production applications.
Adapted to serum-free suspension culture, the CAP-TTM cell line exhibits high protein expression and shows post-translational modifications that are human-like including authentic human glycosylation patterns.
CEVEC CEO Wolfgang Kintzel said, "We’re very pleased that they will add our CAP-T cells to their cell based assay technology portfolio and we’re convinced that the cells will contribute significantly to the drug discovery process in the pharma industry."
Cell Culture Services managing director Oliver Wehmeier said the CAP-TTM cells meet all requirements for a host cell line in terms of robustness, transfection efficacy, expression level, and scalability.
"We obtained outstanding results from transient transfections of various secreted, intracellular, or membrane bound target proteins in CAP-T cells and we are pretty sure that this expression system will be of great benefit to our customers," Wehmeier added.